Capital increase 2026
Below you find further information about the capital increase that was resolved by the Management Board of OncoRedox with approval of the Supervisory Board on July 3, 2026.
NOTE:
This website and the information contained therein do
not constitute an offer to sell or a solicitation of an offer to
buy any securities of OncoRedox in the United States of America
(“U.S.”) or in any other jurisdiction or to any person if such
offer or solicitation is unlawful or not authorized. Users of this
website are requested to inform themselves about and to observe
any such restrictions. The information set forth on this website
must not be distributed in or to the U.S., to “U.S. persons” as
defined in Regulation S under the U.S. Securities Act of 1933, as
amended (the “Securities Act”), or to publications with a general
circulation in the U.S. Each violation of such limitations may
constitute a violation of applicable securities laws of the U.S.
The shares of OncoRedox (the “Shares”) have not been and will not
be registered under the Securities Act and may not be offered or
sold in the U.S. unless pursuant to an exemption from registration
requirements.
| Subscription offer (German only) |
For further information, please don ’t hesitate to contact us:
OncoRedox
Ziegelhäuser Landstraße 3
69120 Heidelberg
Contact:
E-Mail: info@oncoredox.com